Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire reports wider range of Vyvanse dosage strengths

Shire reports wider range of Vyvanse dosage strengths

7th January 2008

Shire has announced that the approval of a wider range of dosage strengths of Vyvanse (lisdexamfetamine dimesylate) could facilitate the improved customisation of treatment for individual attention deficit hyperactivity disorder (ADHD) patients by doctors.

In addition to its existing dosages of 30 mg, 50 mg and 70 mg, the compound has now been approved by the US Food and Drug Administration for sale in pharmacies in 20 mg 40 mg and 60 mg doses.

The firm reports that dose titration is an often-used method to achieve optimal efficacy and tolerability of a drug for each patients, with smaller increments of dosage strengths enabling a more gradual titration of medication to better personalise treatment for each patients.

Matt Emmens, chief executive officer of Shire Pharmaceuticals, said: “Shire is pleased that physicians will soon have the benefit of a wider range of Vyvanse dosage strengths which they can prescribe to help manage the ADHD symptoms of their patients.”

He added that over 500,000 prescriptions for Vyvanse have been dispensed since it was first made available, showing how doctors view the compound as an effective means of treating their patients.

In July 2007, Shire announced that Vyvanse has been proven to provide effective and consistent control of ADHD.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.